|Title:||A small change in FVC but a big change for IPF? Nindetanib and pirfenidone, experience of a tertiary referral centre in the Republic of the Ireland.|
|Author(s):||PK Coghlan E. Lim Man Yu MF Iftikhar L Al Haddah A O’Brien|
|Institution:||University Hospital Limerick|
|Poster:||Click to view poster|
|Abstract:||Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. Pirfenidone and nintedanib are well established as first-line therapy in idiopathic pulmonary fibrosis (IPF). The purpose of our study was to look at objective data available to us for our IPF patients who had been started on targeted anti-fibrotic therapy and compare the experience. |
We reviewed the charts and records of all IPF patients (162) who were treated with anti-fibrotic medication during the period between 1 December 2012 and 30 April 2020 and whose clinical and pulmonary function records were complete for at least a 12-month period.
After 1 year, lung function test parameters of patients treated with pirfenidone and nintedanib had remained stable from baseline with no significant differences in FVC, TLC and DLCO. Nindetanib outperformed pirfenidone in terms of exacerbation rate, radiological progression of disease and adverse drug events over the course of the treatment course evaluated.
This study emphasizes that both nindetanib and pirfenidone remain good therapeutic choices in slowing lung function decline albeit in the context of a disease with enduring mortality.